Price Alert: Shares of 908 Devices (MASS) Trade 5.04% Higher at Midday August 5

Equities Staff  |

Shares of 908 Devices Inc (NASDAQ: MASS) are up 5.04% Friday.

As of 11:56:54 est, 908 Devices is currently sitting at $25.07 and has risen $1.21 per share in trading so far.

908 Devices has moved 12.84% over the last 30 days and has moved YTD 5.22% based on the previous close.

The company expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on 908 Devices visit the company profile.

About 908 Devices Inc

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the U.S. Border Patrol selected the MX908® – a handheld, battery-powered, mass spectrometry device – to standardize its trace drug detection at 20 field locations across the U.S. borders, from North to South and in the Caribbean. The U.S. Border Patrol purchased more than 60 MX908 units, which are designed for rapid analysis of vapor, liquid and solid materials of unknown identity, to prevent drug smuggling and to work with local and state law enforcement in support of its counter drug mission.

To get more information on 908 Devices Inc and to follow the company's latest updates, you can visit the company's profile page here: 908 Devices Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content